Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
1995-05-12
2001-12-11
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S505000, C514S866000
Reexamination Certificate
active
06329361
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the treatment of adult-onset non-insulin dependent diabetes mellitus (NIDDM). More specifically, the invention relates to the treatment of this form of diabetes by administering high doses of chromium in the form of chromic picolinate.
BACKGROUND
Diabetes is known to affect at least 10 million Americans, and millions more may unknowingly have the disease. In the form of this disease known as Type II, non-insulin dependent, or adult-onset (as opposed to juvenile diabetes), the pancreas often continues to secrete normal amounts of insulin. However, this insulin is ineffective in preventing the symptoms of diabetes which include hyperglycemia, impaired carbohydrate metabolism, glycosuria and decreased insulin sensitivity. These symptoms, if left untreated, often lead to severe complications.
Chromium is a nutritionally essential trace element. The essentiality of chromium in the diet was established in 1959 by Schwartz, as cited in
Present Knowledge in Nutrition
, page 571, fifth edition (1984, The Nutrition Foundation, Washington, D.C.). Chromium depletion is characterized by the disturbance of glucose, lipid and protein metabolism and by a shortened lifespan. Chromium is essential for optimal insulin activity in all known insulin-dependent systems (Boyle et al.,
Southern Med. J.,
70:1449-1453, 1977). Insufficient dietary chromium has been linked to both maturity-onset diabetes and to cardiovascular diseases.
The principle energy sources for the body are glucose and fatty acids. Chromium depletion results in biologically ineffective insulin and compromised glucose metabolism. Under these conditions, the body must rely primarily on lipid metabolism to meet its energy requirements, resulting in the production of excessive amounts of acetyl-CoA and ketone bodies. Some of the accumulated acetyl-CoA is diverted to increased cholesterol biosynthesis, resulting in hypercholesterolemia. Diabetes mellitus is characterized in large part by glycosuria, hypercholesterolemia, and often ketoacidosis. The accelerated atherosclerotic process seen in diabetics is associated with hypercholesterolemia (Boyle et al., Supra).
Current drugs used for managing Type II diabetes fall within two classes of compounds: the biguanides and the sulfonylureas. The biguanides, e.g. Metformin, have been approved for use in the U.S. due to induction of lactic acidosis. The sulfonylureas, e.g. tolbutamide and glyburide, lower plasma glucose primarily by stimulating insulin secretion and by enhancing insulin effects in some target tissues and by inhibiting hepatic glucose synthesis.
Supplementation of chromium to normal individuals has been reported to lead to improvements in glucose tolerance, serum lipid concentrations, including high-density lipoprotein cholesterol, insulin and insulin binding (Anderson,
Clin. Physiol. Biochem.,
4:31-41, 1986). Supplemental chromium in the trivalent form, e.g. chromic chloride, is associated with improvements of risk factors associated with adult-onset diabetes and cardiovascular disease.
Chromium is known to function as a co-factor for the action of insulin. It binds to insulin and potentiates many, and perhaps all, of its functions (Boyle et al., supra). These functions include, but are not limited to, the regulation of carbohydrate and lipid metabolism (
Present Knowledge in Nutrition
, supra, at p. 573-577).
The introduction of organic chromium compounds per se into individuals is not particularly beneficial. Chromium must be converted endogenously into an organic complex or must be consumed as a biologically active molecule. Only about 0.5% of ingested organic chromium is assimilated into the body (
Recommended Daily Allowances
, Ninth Revised Edition, The National Academy of Sciences, page 160, 1980). Only 1-2% of most chromium compounds is assimilated into the body.
U.S. Pat. No. 4,315,927 describes the discovery that when selected essential metals are administered to mammals as exogenously synthesized coordination complexes of picolinic acid, they are directly available for absorption into the system without competition from other metals. This patent describes a composition and method for selectively supplementing the essential metals in the human diet and for facilitating absorption of these metals by intestinal cells. These complexes are safe, inexpensive, biocompatible and easy to produce. These exogenously synthesized essential metal coordination complexes of picolinic acid (pyridine-2-carboxylic acid) have the following structural formula:
wherein M represents the metallic cation and n is equal to the cation's valence. For example, when M is Cr and n=3, then the compound is chromic tripicolinate. Other chromium picolinates could include M═Cr
+3
and n=2 (chromic dipicolinate) or n=1 (chromium monopicolinate).
The U.S. Recommended Daily Allowance (RDA) for chromium is 50-200 micrograms. U.S. Pat. No. 5,087,623 describes the administration of chromic tripicolinate for the treatment of adult-onset diabetes in doses ranging from 50 to 500 micrograms.
Thus, there is a need for a safe, effective, inexpensive composition capable of significantly lowering blood sugar levels to an acceptable value. The present invention satisfies this need.
SUMMARY OF THE INVENTION
We have unexpectedly discovered that chromic tripicolinate administered at doses an order of magnitude higher than the RDA can dramatically lower blood glucose levels in individuals having adult-onset diabetes.
The present invention provides a method for reducing hyperglycemia and stabilizing the level of serum glucose in humans comprising administering between about 1,000 and 10,000 micrograms per day of chromium as synthetic chromic tripicolinate to a human in need thereof. Preferably, the amount of chromium administered is between about 1,000 and 5,000 micrograms per day of chromium as synthetic chromic tripicolinate. The chromic tripicolinate is advantageously provided in a pharmaceutically acceptable carrier. According to one aspect of this preferred embodiment, the chromic tripicolinate is orally administered. Alternatively, the chromic tripicolinate is parenterally administered.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the discovery that doses of chromium, administered in the form of chromic tripicolinate, about an order of magnitude higher than the U.S. RDA, promote a significant reduction in blood glucose levels in individuals with Type II diabetes. This reduction is markedly greater than that seen after administration of chromium doses falling within the RDA of chromium and indicates that high doses of chromium picolinate are effective in stabilizing blood glucose levels.
Because chromium is a cofactor which potentiates the action of insulin, it would be expected that an individual receiving a dosage of chromium at the upper end of the RDA range would bind all available insulin, resulting in a maximal reduction in blood glucose levels. In view of this, administration of chromium doses significantly higher than the RDA would not be expected to exert a blood glucose-lowering effect beyond that seen at the upper end of the RDA range, due to saturation of the chromium binding sites on all of the available insulin. Unexpectedly, a daily dose of 1,000 micrograms of chromium administered as chromium tripicolinate, five times higher than the upper limit of the proposed recommended daily intake (120 &mgr;g per day for chromium) significantly reduced blood glucose levels as assessed by a reduction in glycosylated hemoglobin. The therapeutic benefit of chromium tripicolinate is thus clearly dose-dependent, and dosages falling within the so-called “nutritional range” are unlikely to be of significant therapeutic benefit in the treatment of Type II diabetes.
The synthesis of chromic picolinates is described in U.S. Pat. No. 5,087,623, the entire contents of which are hereby incorporated by reference. In order to reduce the requirement for insulin and/or diabetic drugs and to reduce several i
Goldberg Jerome D.
Knobbe Martens Olson & Bear LLP
Nutrition 21
LandOfFree
High-dose chromic picolinate treatment of type II diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High-dose chromic picolinate treatment of type II diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-dose chromic picolinate treatment of type II diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2583599